Substitu	te for form 1449A/P	то			Complete if Known	
·				Application Number	Unassigned	
INFO	DRMATION	I DIS	CLOSURE	Filing Date	Filed Herewith	
STA	TEMENT E	3Y A	PPLICANT	First Named Inventor	Schenk, Dale B.	
1			•	Art Unit	Unassigned	
	(use as many sh	eels as	necessary)	Examiner Name	Unassigned	•
Sheet	1	of	3	Attorney Docket Number	015270-008930US	

			U.S. PATEN	T DOCUMENT	TS+	•
	L	Document Number				·
Examiner Initials*	Cite No.1	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Applican	ne of Patentee or at of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
MH	AA	US-5,958,883	09-28-1999		Snow .	
	AB	US-5,851,996 .	12-22-1998		Kline	
	AC	US-5,780,587	07-14-1998		Potter	
						
	 					
一	<u> </u>			- -	•	•
- -						
╁						
				, .		
			· <u>··</u>		·	
					·	
-						<u></u>
						•
			·		· ·	•
		•	FOREIGN PAT	ENT DOCUME	NTS	
xaminer	Cite	Foreign Patent Docu			Name of Patentee o	Pages, Columns, Lines, Where Relevant
Initials*	No.1	1		Publication Date MM-DD-YYYY	Applicant of Cited	Passages or Relevant

				•	FOREIGN PA	TENT DOCUME	NTS		
F	,	0.1-	For	eign Patent Doc	ument	-	Name of Salastan as	Pages, Columns, Lines,	
	Examiner Cite Initials* No.1		Country Code ³	Number ⁴	Kind Code ¹ (<i>il known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	70
		AD	wo	99/60024	Al	11-25-1999		-,	
1	1	AE	wo	99/06545	A2	02-11-1999			
		AF	wo	91/16819	Al	11-14-1991	•		
						•			

Examiner Signature	Date Considered	
Signature	Considered	·

Substitute fo	or form 1449B/PT	·o			Complete if Known
INFO	OREATION	DICC	OCUDE	Application Number	Unassigned
	-		LOSURE	Filing Date	Filed Herewith Schenk, Dale B.
STATI	EMENT E	BY APP	PLICANT	First Named Inventor	
				Art Unit	Unassigned
(U.	se as many sh	eets as ne	cessary)	Examiner Name	Unassigned
Sheet	2 .	of	3	Attorney Docket Number	015270-008930US

١.		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
MH	AG	CHAPMAN, P.F., "Model behaviour," Nature, 408:915-916 (2000).	
	АН	CONWAY et al., "Acceleration of oligomerization, not fibrillization, is a shared property of both \(\alpha\)-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy," PNAS, 97(2):571-576 (2000).	
	AI	DEMATTOS et al., "Peripheral anti A β antibody alters CNS and plasma A β clearance and decreases brain A β burden in a mouse model of Alzheimer's disease," PNAS, 10:1-6 (2001).	
·	LA.	ELAN, "Elan and AHP provide an update on the phase 2A Clinical Trial of AN-1782," Press Release of 1/28/02.	
	AK	ELAN, "Elan and Wyeth provide update on status of Alzheimer's collaboration," Press Release of 3/1/02.	
	AL	ESIRI, M.M., "Is an effective immune intervention for Alzheimer's disease in prospect?," <u>Trends in Pharmacological Sciences</u> , 22(1):2-3	
	AM	FRENKEL et al., "N-terminal EFRH sequence of Alzheimer's β-amyloid peptide represents the epitope of its anti-aggregating antibodies," Journal of Neuroimmunology, 88:85-90 (1998).	
	, AN	FRENKEL et al., "Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration," PNAS, 97(21):11455-11459 (2000).	
	AO	FRENKEL et al., "High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β-amyloid peptide is essential for modulation of fibrillar aggregation," Journal of Neuroimmunology, 95:136-142 (1999).	
·	AP	FRIEDLAND et al., "Neuroimaging of Vessel Amyloid in Alzheimer's Disease a.b." from Cerebrovascular Pathology in Alzheimer's Disease, eds. de la Torre and Hachinski, New York Academy of Science, NY, NY, pages 242-247 (1997).	
	AQ	GAMES et al., "Alzheimer-type neuropathology in transgeneic mice overexpressing V717F β-amyloid precursor protein," Nature, 373(6514):523-527 (1995).	
	AR	GRUBECK-LOEBENSTEIN et al., "Immunization with β-amyloid: could T-cell activation have a harmful effect?," <u>TINS</u> , 23(3):114 (2000).	
	AS	JEN et al., "Preparation and purification of antisera against different regions or isoforms of β-amyloid precursor protein," <u>Brain Research Protocols</u> , 2:23-30 (1997).	
	AT	JOBLING et al., "Analysis of structure and function of the B subunit of cholera toxin by the use of site-directed mutagenesis," Molecular Microbiology, 5(7):1755-1767- (1991).	
	ΑU	LEMERE et al., "Nasal A& Treatment Induces Anti-A& Antibody Production and Decreases Cerebral Amyloid Burden in PD-APP Mice," Annals of NY Acad. Sci., 920:328-331 (2000).	
V	AV	MASLIAH et al., "β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease," PNAS, 98(21):12245-12250 (2001).	

Examiner	Date	•
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English tanguage Translation is attached.

Substituté fe	or form 1449B/P	то [.]			Complete if Kn wn	
INFO	A A TIO	N DISCI	LOSURE	Application Number	Unassigned	
				Filing Date	Filed Herewith	
SIAII	EMENI	BY APP	LICANT	First Named Inventor	Schenk, Dale B.	
				Art Unit	Unassigned	
(U	se as many s	heets as ne	cessary)	Examiner Name	Unassigned	
Sheet	. 3	of	_ 3	Attorney Docket Number	015270-008930US	

	1	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	7			
МН	AW	PERUTZ et al., "Amyloid fibers are water-filled nanotubes," PNAS, 99(8):5591-5595 (2002).				
	AX	RASO, V., "Immunotherapy of Alzheimer's Disease," Immunotherapy Weekly, abstract, (1999).				
AY SCHENK et al., "Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAF mouse," Nature, 400:173-177 (1999).						
	AZ	SKOLNICK et al., "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <u>Trends in Biotechnology</u> , 18(1):34-39 (2000).				
	ВА	SMALL et al., "Alzheimer's disease and Aß toxicity: from top to bottom," Nat. Rev. Neurosci., 2(8):595-598 (2001).				
	ВВ	ST GEORGE-HYSLOP et al., "Antibody clears senile plaques," Nature, 400:116-117 (1999).				
$\sqrt{}$	ВС	YOUNKIN, S.G., "Amyloid β vaccination: reduced plaques and improved cognition," Nature Medicine, 7(1):18-19 (2001).	1			
			5			
			T			

Examiner Signature	/ /Michelle Horning/	Date	11/07/2006
Signature	/Michelie Horning/	Considered-	11/07/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-03)

Substitute for form 1440APTO						Complete if Known	
INFORMATION DISCLOSURE					Application Number	Unassigned	
					Filing Date	October 31, 2003	
STAT	EMENT	BY A	IPPLI	CANT	First Named Inventor	Schenk, Dale B.	
_					Art Unit	Unassigned	
(use as many sheets as necessary)			ny)	Examiner Name	Unassigned		
Sheet	1	of	<u> </u>	1	Attorney Docket Number	015270-008930US	

			U.S. PATENT DO	CUMENTS+		
		Document Number				
iviliale. Exalsivel	Cite No.	Number Cind Code ² (Fibrown)	Publication Data MM-OD-YYYY	Name of Patenies of Applicant of Clad Document	Pages, Columna, Lines I Ralevani Passages or Pa Agures Appear	ijavajit Sijavaji
МН	AA	2002/0197258 A1	12-26-2002	Ghanbari et al.		•

Examiner	/364 - 1 - 1 1 - 22 1 /			
Signature	/Michelle Horning/	Date		
OiBriennie.		Considered	11/07/2006	

EXAMINER: Initial if reference considered, whether or not chaden is in conformance with MPEP and. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique chatten designation number (optional). Kind Codes of U.S. Patent Documents at www.uspin.com or MPEP and. Applicant's unique chatten designation number (optional). Standard ST.3). For plagances patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. Applicant is to place a check mark here if English tenguage Translation is ettached.

PAGE 13/13 * RCVD AT 12/29/2003 11:26:57 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/2 * DNIS:8729306 * CSID:16503262422 * DURATION (mm-ss):03-12

SEP 0 7 2004 W

Distitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	•	•			•
Sheet	l 1		of	1	

	Complete if Known
Application Number	10/698,099
Filing Date	October 31, 2003
First Named Inventor	Schenk, Dale B.
Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	015270-008930US

			U.S. PATENT DO	CUMENTS+	
		Document Number	Publication Date	Name of Patentee or	Pages Columns Harr Marry
Examiner Initials*	Cite No. ¹	Number Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
MH	415	US 2003/0168558 A1	09-04-2003	Frangione et al.	
	•	-			
			· · · · · · · · · · · · · · · · · · ·		
		<u> </u>			
				<u> </u>	
· ·					
					,

				FOREIGN PA	TENT DOCUME	NTS		
F		Fon	eign Patent Doo	ument		Name of Patentee or	Pages, Columns, Unes,	
Examiner Initials*	Cite No.1	Country Code ³	Number ⁴	Kind Code ⁸ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ^o
		1						
							•	

Examiner		Date		
Signature	/Michelle Horning/	Considered	11/07/2006	
0.8	/micherie noining/	00.10.00.00	11/0//2006	•

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

SEP 2 8 2004 55

Superjute for form 1449A/PTO

NFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

	Complete if Known
Application Number	10/698,099
Filing Date	October 31, 2004 '
First Named Inventor	Schenk, Dale B.
Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	015270-008930US

			U.S. PÁTENT DO	CUMENTS+	
		Document Number	J		
Examiner Initials*	Cite No.	Number Kind Code ² (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
			,		
				·	•
				·	
			· · · · · · · · · · · · · · · · · · ·		
				<u> </u>	
					•
				<u> </u>	
-				<u> </u>	•
		1	<u> </u>		

				FOREIGN PA	TENT DOCUME	NTS		
Examiner Initials*	Cite No.1	For Country Code ³	eign Patent Doo Number ⁴	Curnent Kind Code* (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T [®]
MH	AA	wo	01/06989	. A2	02-01-2001			
	AB	wo	00/72880	A2	12-07-2000			
\/	AC	wo	00/72876	A2	12-07-2000			
•			<u>-</u>					├
		 			· · · · ·			
						· · · · · · · · · · · · · · · · · · ·		

	Examiner Signature	/Michelle Horning/	Date Considered	11/07/2006		
--	-----------------------	--------------------	--------------------	------------	--	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. If Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known		
INFORMATION DISCLOSURE			LOCUET	Application Number	10/698,099	
	INFORMATION DISCLOSURE			Filing Date	October 31, 2003	
STATI	STATEMENT BY APPLICANT		First Named Inventor	Schenk, Dale B.		
	•			Art Unit	1614	
(U:	se as many s	heets as ne	ecessary)	Examiner Name	Unassigned	
Sheet	2	of	2	Attomey Docket Number	015270-008930US	

	T	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	τ2
MH	AD	BODLES et al., "Toxicity of non-A β component of Alzheimer's disease amyloid, and N-terminal fragments thereof, correlates to formation of β -sheet structure and fibrils," <u>Eur J. Biochem.</u> , 267:2186-2194 (2000).	
	AE	CAO et al., "Development of an Alpha Synuclein Recombinant Protein as a Potential Candidate Against Parkinson's Disease," Program No. 594.13, Abstract Viewer/Itinerary Planner, Washington D.C.: Society for Neuroscience, 2002.	
	AF	CULVENOR et al., "Non-A\$ Component of Alzheimer's Disease Amyloid (NAC) Revisited, NAC and a-Synuclein Are Not Associated with A\$ Amyloid," Am. J. Pathology, 155(4):1173-1181 (1999).	
	AG .	HASHIMOTO et al., "Alpha-synuclein in Lewy Body Disease and Alzheimer's Disease," Brain Pathology, 9:707-720 (1999).	
	АН	HSU et al., "c-Synuclein Promotes Mitochondrial Deficit and Oxidative Stress," Am. J. Pathology, 157(2):401-410 (2000).	
	'AI	JENSEN et al., "Residues in the synuclein consensus motif of the alpha-synuclein fragment, NAC, participate in transglutaminase-catalysed cross-linking to Alzheimer-disease amyloid beta A4 peptide," <u>Biochem. J.</u> , 310(Pt 1):91-94 (1995).	
	AJ	MASLIAH et al., "Dopaminergic Loss and Inclusion Body Formation in α-Synuclein Mice: Implications for Neurodegenerative Disorders," Science, 287:1265-1268 (2000).	
	AK	NCBI database search result for P37840 Alpha-synuclein conducted 10/21/02 at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&DB=protein&list_uids=58	
	AL	NCBI database search result for NP_009292 synuclein, alpha conducted 10/21/02 at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=protein&list_uids=68	
V	AM	UEDA et al., "Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease," PNAS, 90:11282-11286 (1993).	

Examiner Signature	/Michelle Horning/	Date Considered	11/07/2006